Researchers suggest people taking Ozempic and similar drugs may face double the risk of developing wet age-related macular ...

The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure ...

Ocular Therapeutix is making sure its corporate vision is 20/20 as it looks forward to phase 3 data on its eye disease drug candidate Axpaxli. | Ocular Therapeutix is making sure its corporate vision ...

Before drugs were developed to treat wet AMD, the main treatment was a procedure known as laser photocoagulation, which used a laser beam to seal leaking blood vessels. [11] ...

A recent study found that older adults with diabetes who use a GLP-1 drug have double the risk of developing wet age-related ...

However, at the 18–30 month mark, GLP-1 users’ risk of developing wet AMD more than doubled compared to non-users. And those taking the drugs for 30 months or longer had more than triple the risk.

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire wet age-related macular degeneration (AMD) program.. Sozinibercept ...

The Food and Drug Administration (FDA) has accepted for review a resubmission of the Biologics License Application (BLA) for bevacizumab-vikg (ONS-5010) for the treatment of wet age-related ...

BERKELEY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced its president and chief scientific ...

Canadian researchers find that taking semaglutide increases the chances of developing neovascular age-related macular ...